Compare Johnson & Johnson (JNJ) vs Vanguard Intermediate Term Corporate Bond ETF (VCIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Vanguard Intermediate Term Corporate Bond ETF — how do they compare? Johnson & Johnson trades at $259.9 (market cap $626.09B), while Vanguard Intermediate Term Corporate Bond ETF trades at $81.25. The key difference: Johnson & Johnson pays a 2.06% dividend while Vanguard Intermediate Term Corporate Bond ETF pays none, and Johnson & Johnson is trading nearer its 52-week high, Vanguard Intermediate Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| JNJ | VCIT | |
|---|---|---|
Market Cap | $626.09B | — |
Volume | 6,156,228 | — |
Sector | Health | Fixed Income |
52-Week High | $267.24 | $84.82 |
52-Week Low | $172.78 | $81.07 |
Enterprise Value | $654.37B | — |
Dividend Yield | 2.06% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $261.81, up 0.99% on the day and near its 52-week high. The stock exhibits bullish technical signals with strong moving average support, while fundamentals show robust profitability with a net income margin of 21.48% and consistent dividend growth. Recent earnings have mostly beaten expectations, and the company maintains a solid balance sheet with $24.52 billion in cash.
The outlook for JNJ remains positive, supported by analyst consensus and a price target of $284.50. Key opportunities include its defensive healthcare positioning and pipeline strength, though risks involve patent expirations and legal headwinds. The stock offers a stable investment with growth potential in a volatile market.
VCIT, the Vanguard Intermediate-Term Corporate Bond ETF, trades at $81.295 with a modest 0.28% daily gain. Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators remain neutral. The fund maintains competitive advantages with its ultra-low 0.03% expense ratio and approximately 5% yield, holding over 2,000 investment-grade corporate bonds. Recent dividend distributions of $0.33-0.34 highlight its income-focused strategy.
The outlook for VCIT remains favorable for income investors seeking corporate bond exposure with low costs. Key opportunities include the fund's yield advantage over treasury alternatives and consistent monthly distributions. Risks involve interest rate sensitivity and corporate credit quality concerns during economic uncertainty. Wall Street sentiment is generally positive given the fund's cost efficiency and diversification benefits.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Vanguard Intermediate Term Corporate Bond ETF
VCIT tracks the Bloomberg U.S. 5-10 Year Corporate Bond Index, providing exposure to investment-grade debt from industrial, utility, and financial companies. It acts as a middle-ground bond fund, offering higher yields than short-term bonds with less price volatility than long-term corporate debt.
Read more on VCIT →
